PharmaCyte (PMCB) Director Jonathan Schechter Reports Canceled Grant

What Happened
Jonathan Schechter, a director of PharmaCyte Biotech, filed an amended Form 4 reporting an "other acquisition or disposition (J)" on March 31, 2026 that shows 0 shares acquired (derivative) at N/A. The filing includes a footnote stating the reported grant was made in error and has been cancelled, so no securities were actually received and there is no purchase or sale value.

Key Details

• Transaction date: 2026-03-31 (reported on an amended Form 4 filed 2026-07-17)
• Reported transaction: Code J — Other acquisition/disposition (derivative); 0 shares @ N/A (no value)
• Footnote: The reported grant was made in error and has been cancelled (F1)
• Shares owned after transaction: not changed/none reported as a result of this entry
• Filing status: This is an amended, belated filing correcting the original report (Form 4 normally must be filed within 2 business days)

Context
This was a corrective entry for a mistakenly reported derivative award; it does not represent a purchase, sale, exercise, or other economic change in holdings. For investors, canceled/error filings correct the record but do not imply insider trading intent or a change in insider sentiment.